Table 3.
Patients’ characteristics.
| Nr | Sex | Age | Subtype | Stage | Anti-PD-1 Inhibitor | Line | Previous lines of therapy |
|---|---|---|---|---|---|---|---|
| P-18 | F | 60 | Solid | Local recurrence, metastatic (bone) | Camrelizumab | 1 | |
| P-05 | M | 51 | Solid | Local recurrence, metastatic (bone, mediastinal lymph nodes) | Camrelizumab | 2 | Paclitaxel,cisplatin |
| P-30 | F | 71 | Unknown | Metastatic (lung, mediastinum, pleura) | Pembrolizumab | 2 | Apatinib |
| P-08 | M | 28 | Mixed | Metastatic (lung) | Camrelizumab | 4 | Apatinib/Everolimus/Docetaxel, Nedaplatin |
| P-17 | M | 29 | Mixed | Metastatic (lung, adrenal gland) | Camrelizumab | 2 | Apatinib |